Approved indications: Turalio is FDA-approved only for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) that causes substantial functional limitations or severe morbidity and is not amenable to improvement with surgery.

Off-label or investigational uses: Pexidartinib has been studied in small trials and case reports for certain leukemias, solid tumors, and rare histiocytic disorders (such as some Erdheim–Chester disease cases), but these uses are investigational, generally restricted to clinical trials or highly selected situations, and it is not an established off-label treatment for other conditions.

Efficacy expectations in TGCT: In the main ENLIVEN study, about 4 in 10 patients had major tumor shrinkage by 6 months, and with longer follow-up roughly 6 in 10 eventually responded, with many maintaining benefit for years while on treatment; stiffness, range of motion, and physical function typically begin to improve over the first few months, though pain relief is often more modest and some patients still require surgery or do not respond.

Comparison to other options: For advanced or diffuse TGCT that cannot be adequately managed with surgery, Turalio is currently the only systemic therapy specifically approved and generally shows higher and more durable response rates than other tyrosine kinase inhibitors studied off-label, but its use is limited by the risk of serious liver toxicity and the need for intensive monitoring.

Typical adult dosing: For adults with TGCT, the recommended dose is 250 mg of Turalio taken by mouth twice daily (total 500 mg per day), with a low-fat meal containing about 11–14 grams of fat, continued as long as the tumor is controlled and side effects remain acceptable.

How to take it: Swallow capsules whole with water without opening, crushing, or chewing; take the morning and evening doses about 12 hours apart with similar low-fat meals each day, avoid high-fat meals that can raise drug levels and liver risk, and avoid proton pump inhibitors; if you must take an antacid, usually you take Turalio 2 hours before or 2 hours after it, and if you use an H₂-blocker, you typically take Turalio at least 2 hours before or 10 hours after that medicine.

Special dosing instructions: Lower doses are used if you have moderate liver impairment, reduced kidney function, or need certain interacting drugs (such as strong CYP3A or UGT inhibitors), and your healthcare team may interrupt or reduce the dose if liver tests or other side effects become concerning; your exact dosing schedule should always follow your prescriber’s instructions.

Missed doses and overdose: If you miss a dose or vomit after taking a dose, do not take an extra capsule—simply take your next dose at the regular scheduled time; if you take more than prescribed or suspect an overdose, seek emergency care or contact a poison control center right away.

Common side effects: Very common effects include changes in hair color, fatigue, nausea, altered or decreased taste, rash or itching, and swelling around the eyes, and blood tests often show increases in liver enzymes, cholesterol, or changes in blood counts; these usually appear in the first weeks to months and are often mild to moderate but sometimes lead to dose reduction or interruption.

Serious or rare adverse effects: Turalio has a boxed warning for severe and potentially fatal liver injury, including cholestatic damage and vanishing bile duct syndrome, which can present with intense itching, yellowing of the skin or eyes, dark urine, pale stools, right upper abdominal pain, fever, or profound tiredness and requires immediate medical attention; rare risks also include severe allergic reactions, significant high blood pressure, and serious drops in blood counts.

Warnings and precautions: Because of its liver toxicity risk, Turalio is dispensed only through the Turalio REMS program, with strict liver-test monitoring; it can harm an unborn baby, so people who can become pregnant should use effective non-hormonal contraception during treatment and for a short period afterward, and breastfeeding is not recommended during therapy and for at least 1 week after the last dose; use in children is not established, and the drug should be avoided in people with significant pre-existing liver or biliary disease and used cautiously with dose adjustment in moderate liver or kidney impairment.

Relative safety profile: Compared with other oral kinase inhibitors that have been tried off-label for TGCT, Turalio offers greater likelihood of tumor shrinkage but carries a unique and well-documented risk of serious cholestatic liver injury, making careful patient selection and adherence to monitoring especially important.

Reporting and safety updates: Side effects can be reported to the FDA MedWatch program or to the manufacturer, and up-to-date safety information is provided in the Turalio Medication Guide, on the Turalio REMS website, and through FDA drug safety communications.

Major drug and food interactions: Strong or moderate CYP3A or UGT inhibitors (such as some azole antifungals, macrolide antibiotics, and certain HIV or hepatitis C antivirals, or the UGT inhibitor probenecid) can substantially increase Turalio levels and the risk of side effects, while strong CYP3A inducers (for example rifampin, carbamazepine, phenytoin, and St John’s wort) can lower levels and reduce effectiveness; grapefruit and grapefruit juice should be avoided because they act like CYP3A inhibitors and can cause excessive drug exposure.

Effects on other medicines and contraception: Pexidartinib can induce CYP3A and affect drug transporters, so it may lower blood levels of some other medicines, including hormonal contraceptives, potentially making them less effective, and can modestly alter levels of CYP2C9 substrates and some transporter substrates (such as certain statins or metformin-like drugs), so prescribers often review and sometimes adjust other medications.

Acid-reducing agents, OTC drugs, and supplements: Proton pump inhibitors are generally avoided with Turalio; if antacids or H₂-blockers are needed, doses are separated in time as directed to limit interaction, and patients are usually advised not to use St John’s wort or high-dose herbal supplements without explicit medical approval.

Precautions and conditions making use unsafe or higher risk: Turalio should not be started in people with abnormal baseline liver tests or active liver or bile-duct disease, and it is used cautiously in those with prior serious liver injury, moderate hepatic impairment, or reduced kidney function; it is not established for use in children or during pregnancy or breastfeeding, and careful review is needed in anyone taking other potentially hepatotoxic drugs or with heavy alcohol use.

Monitoring needs: Liver-function blood tests are required before treatment, weekly for the first 8 weeks, every 2 weeks for the next month, and then about every 3 months, and clinicians may also periodically monitor blood counts, cholesterol, kidney function, and blood pressure to detect treatment-related problems early.

Q: What is Turalio prescribed for?
A: Turalio is prescribed for adults with symptomatic tenosynovial giant cell tumor (TGCT) that causes serious joint problems or disability and is not likely to improve enough with surgery alone.

Q: How long does it take for Turalio to start working?
A: Some people notice improvements in stiffness or function within a few months, but meaningful tumor shrinkage and symptom relief often develop gradually over 3 to 6 months or longer, and treatment is usually continued as long as it is helping and tolerated.

Q: Will Turalio cure my TGCT or replace surgery?
A: Turalio can shrink tumors, improve movement, and reduce symptoms, but it does not "cure" TGCT, and some patients may still need surgery or have persistent or recurrent disease despite treatment.

Q: What are the most serious risks I should watch for?
A: The main serious risk is liver injury, so you should watch for intense itching, yellowing of the skin or eyes, dark urine, pale stools, right-sided belly pain, or unexplained severe fatigue and report these immediately, and you will have frequent blood tests to check your liver.

Q: Can I drink alcohol while taking Turalio?
A: Alcohol is not absolutely forbidden, but because both alcohol and Turalio can stress the liver, many clinicians recommend avoiding or keeping alcohol to a minimum and never binge drinking while on this medicine.

Q: How long will I need to stay on Turalio?
A: People typically continue Turalio as long as it controls the tumor and side effects remain manageable, which in studies has often meant treatment for many months or even several years, with regular reevaluation by the care team.

Storage: Store Turalio capsules at room temperature (about 68–77°F / 20–25°C), in the original tightly closed bottle with the drying packet inside, protected from moisture and heat, and kept out of the reach of children and pets.

Disposal: When the medication is expired or no longer needed, use a drug take-back program if available; if not, remove the capsules from the bottle, mix them with an undesirable substance (such as used coffee grounds or cat litter), seal the mixture in a bag or container, and place it in the household trash unless your pharmacist gives different instructions.